BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1656890)

  • 1. [Expression of ras oncogene p21 in relation to prognostic factors of human breast cancer].
    Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Ueno Y; Yamashita H; Nomura K; Ichiguchi O
    Gan To Kagaku Ryoho; 1991 Oct; 18(13):2271-5. PubMed ID: 1656890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras p21 immunostaining in early stage squamous cervical carcinoma: relationship with lymph nodal involvement and 72 kDa-metalloproteinase index.
    Garzetti GG; Ciavattini A; Lucarini G; Goteri G; Nictolis MD; Romanini C; Biagini G
    Anticancer Res; 1998; 18(1B):609-13. PubMed ID: 9568185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer.
    Clair T; Miller WR; Cho-Chung YS
    Cancer Res; 1987 Oct; 47(20):5290-3. PubMed ID: 3308076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
    Miyamoto H; Harada M; Isobe H; Akita HD; Haneda H; Yamaguchi E; Kuzumaki N; Kawakami Y
    Cancer Res; 1991 Dec; 51(23 Pt 1):6346-50. PubMed ID: 1657384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
    Huang J; Tan PH; Thiyagarajan J; Bay BH
    Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
    Yaginuma Y; Yamashita K
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of ras Rb1 and p53 proteins in human breast cancer.
    Spandidos DA; Karaiossifidi H; Malliri A; Linardopoulos S; Vassilaros S; Tsikkinis A; Field JK
    Anticancer Res; 1992; 12(1):81-9. PubMed ID: 1567185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical evaluation of P21ras and P53 proteins expression in human non-small-cell lung cancers.
    Przybojewska B; Rydzynski K; Stepnik M; Jakubiak M; Kozak J; Szymczak W
    Neoplasma; 2003; 50(3):198-203. PubMed ID: 12937853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between the expression of the P21 ras oncogene product and the biological behavior of bladder tumors.
    Miao TJ; Wang Z; Sang N
    Eur Urol; 1991; 20(4):307-10. PubMed ID: 1814747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ha-ras oncogene product in human oral squamous cell carcinoma.
    Oku N; Shimada K; Itoh H
    Kobe J Med Sci; 1989 Dec; 35(5-6):277-86. PubMed ID: 2699627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of c-erbB-2 expression in invasive ductal carcinoma of the breast.
    Horiguchi J; Iino Y; Takei H; Morishita Y
    Jpn J Clin Oncol; 1995 Aug; 25(4):119-23. PubMed ID: 7666587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma.
    O'Hanlon DM; Kiely M; MacConmara M; Al-Azzawi R; Connolly Y; Jeffers M; Keane FB
    Eur J Surg Oncol; 2002 Mar; 28(2):103-7. PubMed ID: 11884043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of ras p21 in mammary and extramammary Paget's disease.
    Mori O; Hachisuka H; Nakano S; Sasai Y; Shiku H
    Arch Pathol Lab Med; 1990 Aug; 114(8):858-61. PubMed ID: 1695839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.
    Zhang Z; Yamashita H; Toyama T; Sugiura H; Ando Y; Mita K; Hamaguchi M; Kawaguchi M; Miura Y; Iwase H
    Clin Cancer Res; 2005 Jan; 11(1):193-8. PubMed ID: 15671546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer.
    Li M; Liu W; Zhu YF; Chen YL; Zhang BZ; Wang R
    Acta Oncol; 2006; 45(8):1115-9. PubMed ID: 17118848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas.
    Hand PH; Vilasi V; Thor A; Ohuchi N; Schlom J
    J Natl Cancer Inst; 1987 Jul; 79(1):59-65. PubMed ID: 3298786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ras p21 oncoprotein in normal and neoplastic human endometrium.
    Scambia G; Catozzi L; Benedetti-Panici P; Ferrandina G; Battaglia F; Giovannini G; Distefano M; Pellizzola D; Piffanelli A; Mancuso S
    Gynecol Oncol; 1993 Sep; 50(3):339-46. PubMed ID: 8406198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the long-term effects of intraperitoneal chemotherapy and the expression of p53 and p21 in patients with gastric carcinoma at stage IIIa and stage IIIb.
    Ikeguchi M; Saito H; Katano K; Gomyo Y; Tsujitani S; Maeta M; Kaibara N
    Int Surg; 1997; 82(2):170-4. PubMed ID: 9331847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
    Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
    Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.